Is PHASQ or RYLD a better dividend investment in 2026?

PHASQ currently yields 200000000.00% with a 5% 5-year dividend growth rate. RYLD yields 12.39% with 5% growth. The better choice depends on your goal: PHASQ offers higher current income.

What is the dividend yield difference between PHASQ and RYLD?

PHASQ has a forward dividend yield of 200000000.00% ($2.00/share annually). RYLD yields 12.39% ($1.81/share annually). The yield gap is 199999987.61 percentage points.

Home › Compare › PHASQ vs RYLD

PHASQ vs RYLD: Dividend Comparison 2026

PHASQ yields 200000000.00% · RYLD yields 12.39%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PHASQ wins by $4.875657285131069e+59M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PHASQ

● Live price

200000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.875657285131069e+59M

Annual income

$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00

Full PHASQ calculator →

RYLD

● Live price

12.39%

Share price

$14.64

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$45.3K

Annual income

$2,682.98

Full RYLD calculator →

Portfolio growth — PHASQ vs RYLD

📍 PHASQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PHASQ	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PHASQ + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PHASQ pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHASQ

Annual income on $10K today (after 15% tax)

$17,000,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,053.44/yr

After 10yr DRIP, annual income (after tax)

$2,280.53/yr

At 15% tax rate, PHASQ beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHASQ + RYLD for your $10,000?

PHASQ: 50%RYLD: 50%

100% RYLD50/50100% PHASQ

Portfolio after 10yr

$2.4378286425655345e+59M

Annual income

$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

100.00%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on PHASQ right now

PHASQ

Analyst Ratings

Buy

Hold

Consensus: Hold

Altman Z

-42.8

Piotroski

2/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHASQ buys

RYLD buys

No recent congressional trades found for PHASQ or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPHASQRYLD

Forward yield	200000000.00% ✓	12.39%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.875657285131069e+59M	$45.3K ✓
Annual income after 10y	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓	$2,682.98
Total dividends collected	$4.875656971401711e+59M	$19.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: PHASQ vs RYLD ($10,000, DRIP)

Year	PHASQ Portfolio	PHASQ Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$20,000,010,700	$20,000,000,000.00	$11,939	$1,239.34	+$20000.00M → PHASQ
2	$37,383,218,970,104,910	$37,383,197,570,093,464.00	$14,158	$1,382.89	+$37383218970.09M → PHASQ
3	$65,303,942,472,059,150,000,000	$65,303,902,472,014,860,000,000.00	$16,682	$1,532.59	+$65303942472059152.00M → PHASQ
4	$106,615,009,060,306,890,000,000,000,000	$106,614,939,185,088,440,000,000,000,000.00	$19,537	$1,687.64	+$1.0661500906030689e+23M → PHASQ
5	$162,672,273,967,082,950,000,000,000,000,000,000	$162,672,159,889,023,270,000,000,000,000,000,000.00	$22,752	$1,847.20	+$1.6267227396708296e+29M → PHASQ
6	$231,966,340,306,755,300,000,000,000,000,000,000,000,000	$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00	$26,355	$2,010.43	+$2.319663403067553e+35M → PHASQ
7	$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000	$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00	$30,376	$2,176.45	+$3.091381823051466e+41M → PHASQ
8	$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000	$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00	$34,847	$2,344.43	+$3.850317772522584e+47M → PHASQ
9	$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$39,800	$2,513.54	+$4.481844117993459e+53M → PHASQ
10	$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$45,269	$2,682.98	+$4.875657285131069e+59M → PHASQ

PHASQ vs RYLD: Complete Analysis 2026

PHASQ — Stock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHASQ Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this PHASQ vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHASQ vs SCHD PHASQ vs JEPI PHASQ vs O PHASQ vs KO PHASQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.